Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMMBNASDAQ:EDSAOTCMKTS:ICOTFOTCMKTS:LTUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$1.40+2.6%$1.21$0.78▼$2.55$20.10M0.55212,035 shs127,610 shsEDSAEdesa Biotech$2.01+2.6%$2.26$1.55▼$5.59$14.12M0.55490,370 shs10,399 shsICOTFiCo Therapeutics$0.51-8.7%$0.37$0.80▼$1.82$4.62M2.034,760 shs90,488 shsLTUSLotus Pharmaceuticals$0.01+6.9%$0.01$0.00▼$0.01$16.40M-2.5755,940 shs20,000 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics+2.56%+0.72%+6.87%-14.11%+60.92%EDSAEdesa Biotech+2.55%-0.99%-14.83%-10.43%-54.11%ICOTFiCo Therapeutics0.00%+14.04%+20.95%+1.06%+71.89%LTUSLotus Pharmaceuticals+6.90%+40.91%+3.33%-21.52%+31.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMMBChemomab Therapeutics3.6538 of 5 stars3.55.00.00.03.81.71.3EDSAEdesa Biotech2.6035 of 5 stars3.55.00.00.01.01.70.6ICOTFiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMMBChemomab Therapeutics 3.00Buy$8.50507.14% UpsideEDSAEdesa Biotech 3.00Buy$21.00944.78% UpsideICOTFiCo Therapeutics 0.00N/AN/AN/ALTUSLotus Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ICOTF, LTUS, CMMB, and EDSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.003/13/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/AEDSAEdesa BiotechN/AN/AN/AN/A$0.18 per shareN/AICOTFiCo TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMMBChemomab Therapeutics-$24.22M-$0.76N/AN/AN/AN/A-101.70%-76.18%N/AEDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-233.69%-124.14%8/8/2025 (Estimated)ICOTFiCo Therapeutics-$1.11M-$0.40N/A∞N/AN/AN/A-288.85%N/ALTUSLotus Pharmaceuticals-$20KN/A0.00∞N/AN/AN/AN/AN/ALatest ICOTF, LTUS, CMMB, and EDSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CMMBChemomab Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMMBChemomab TherapeuticsN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMMBChemomab TherapeuticsN/A4.574.57EDSAEdesa BiotechN/A1.090.91ICOTFiCo TherapeuticsN/A0.720.72LTUSLotus PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMMBChemomab Therapeutics46.05%EDSAEdesa Biotech5.50%ICOTFiCo TherapeuticsN/ALTUSLotus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCMMBChemomab Therapeutics11.91%EDSAEdesa Biotech22.60%ICOTFiCo TherapeuticsN/ALTUSLotus PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMMBChemomab Therapeutics2014.36 million12.65 millionNot OptionableEDSAEdesa Biotech207.02 million2.60 millionNot OptionableICOTFiCo TherapeuticsN/A9.05 millionN/ANot OptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableICOTF, LTUS, CMMB, and EDSA HeadlinesRecent News About These CompaniesSperanza Therapeutics Launches New Division to Help Pharma Manufacturers Adapt to Market ShiftsApril 23, 2025 | finance.yahoo.comLotus Pharmaceutical becomes strategic partner for…February 5, 2025 | pharmiweb.comTaiwan’s pharma firm Lotus acquires edema medicine rights in Vietnam from SanofiJanuary 9, 2025 | theinvestor.vnlotus exchangeDecember 28, 2024 | everythingexperiential.businessworld.inBoryung, Lotus Pharma signs CDMO deal on anticancer injectionDecember 12, 2024 | kedglobal.comLotus Pharmaceuticals Inc Price / BookNovember 20, 2024 | investing.comLotus Bakeries: When Growth Potential Meets Pricey ExpectationsNovember 13, 2024 | seekingalpha.comUSA Knotless Surgical Sutures Market Expected to Reach USD 258.7 Million by 2033 at a 3.6% of CAGRNovember 1, 2024 | fmiblog.com20 Shows Like ‘Black Mirror’ That’ll Definitely Mess with Your HeadNovember 1, 2024 | yahoo.comLotus Bakeries: A Sweet Business With Exponential GrowthOctober 27, 2024 | seekingalpha.comA Forbidden Lotus Elise Rival Is for Sale in the U.S. Right NowOctober 24, 2024 | msn.comNatasha Rothwell Opens Up About 'The White Lotus' Season 3, 'How to Die Alone' & MoreOctober 23, 2024 | msn.comLotus Resources Plans Equity Raise for Uranium ProjectOctober 22, 2024 | markets.businessinsider.comLotus of Love Cancer IncOctober 20, 2024 | msn.comThis 90s-Era GM-Lotus Mashup Was The Ultimate Sleeper SedanOctober 19, 2024 | topspeed.comWhy Romantics Love the Lotus Sex Position, According to a SexologistOctober 9, 2024 | popsugar.comTopic: @lotusOctober 9, 2024 | arstechnica.com2025 Lotus Emira Gets 400-HP Turbo SE VersionOctober 9, 2024 | autoevolution.comSee CEO plans as Lotus Bank opens new branch, makes promisesOctober 8, 2024 | msn.comLotus Unveils All-New Performance-Driven Emira Turbo SEOctober 7, 2024 | hypebeast.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeICOTF, LTUS, CMMB, and EDSA Company DescriptionsChemomab Therapeutics NASDAQ:CMMB$1.40 +0.04 (+2.56%) Closing price 05/27/2025 03:58 PM EasternExtended Trading$1.40 0.00 (0.00%) As of 05/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Edesa Biotech NASDAQ:EDSA$2.01 +0.05 (+2.55%) Closing price 05/27/2025 03:53 PM EasternExtended Trading$2.06 +0.05 (+2.49%) As of 05/27/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.iCo Therapeutics OTCMKTS:ICOTFSatellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0062 +0.00 (+6.90%) As of 05/27/2025 03:16 PM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
